(PRWEB) September 11, 2013
A federal panel of judges, after three months of deliberation, denied a motion for consolidation of Lipitor-induced Type 2 diabetes cases, according to an Aug. 8 panel order.* The Rottenstein Law Group LLP, a Lipitor law firm, offers an explanation of what the decision means for those looking to file Lipitor lawsuits.
The U.S. Judicial Panel on Multidistrict Litigation oversees consolidations of federal lawsuits. In its order, the JPML wrote that, “in particular, almost half of the actions currently comprising this litigation are pending in a single district—the District of South Carolina, and many of the actions involve common plaintiffs’ counsel. The South Carolina actions already are proceeding in a coordinated fashion before one judge.”
In the order, the JPML also indicated that Pfizer was willing to coordinate with the plaintiffs with regard to the consolidation of pretrial proceedings such as common discovery, which is the primary purpose of a multidistrict litigation. Therefore, the JPML denied the motion to create an MDL, according to the order.
“The decision of the Panel isn’t controversial, and it certainly should not be discouraging to any potential plaintiff,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “The Panel saw that there are currently a small number of Lipitor suits, most of which are already in the same court. Anyone who has taken Lipitor and suffered adverse side effects has the same opportunity to sue for compensation as always. The Panel decision doesn’t change that at all.”
The Lipitor lawsuits focus on the claim, supported by at least two research studies, that links the use of the drug and a risk of Type 2 diabetes. A 2011 American College of Cardiology study established a connection between the statin and the diabetes risk, and a January 2012 JAMA: Internal Medicine study highlighted the risk in women.**
The Rottenstein Law Group LLP encourages those who have taken Lipitor to download a free informational brochure that discusses Lipitor side effects and how to file a Lipitor lawsuit.
*In Re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation, MDL-2459, JPML. http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2459-Denied_Transfer-07-13.pdf
About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and drugs. (Attorney advertising. Prior results do not guarantee a similar outcome.)
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
Read the full story at http://www.prweb.com/releases/lipitor-lawsuits/diabetes/prweb11110224.htm.
Copyright©2012 Vocus, Inc.
All rights reserved